Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Palovarotene - Clementia Pharmaceuticals

Drug Profile

Palovarotene - Clementia Pharmaceuticals

Alternative Names: Clm-001; R-667; RAR-gamma; RG-667; RO-3300074

Latest Information Update: 29 Apr 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roche
  • Developer Clementia Pharmaceuticals; Roche
  • Class Benzoic acids; Eye disorder therapies; Naphthalenes; Pyrazoles; Small molecules
  • Mechanism of Action Retinoic acid receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Fibrodysplasia ossificans progressiva; Bone disorders
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Fibrodysplasia ossificans progressiva
  • Phase II Bone disorders
  • Phase I Dry eyes
  • Discontinued Emphysema

Most Recent Events

  • 24 Oct 2019 Clementia Pharmaceuticals announces intention to submit NDA to US FDA for Fibrodysplasia ossificans progressiva (In children, In adults) in first quarter of 2020
  • 18 Apr 2019 Clementia Pharmaceuticals has been acquired by Ipsen
  • 09 Apr 2019 Clementia Pharmaceuticals announces intention to submit NDA to the US FDA for Bone disorders in December 2024
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top